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Oral Selinexor–Dexamethasone for TripleClass Refractory Multiple Myeloma
A. Chari, D.T. Vogl, M. Gavriatopoulou, A.K. Nooka, A.J. Yee, C.A. Huff,
P. Moreau, D. Dingli, C. Cole, S. Lonial, M. Dimopoulos, A.K. Stewart, J. Richter,
R. Vij, S. Tuchman, M.S. Raab, K.C. Weisel, M. Delforge, R.F. Cornell,
D. Kaminetzky, J.E. Hoffman, L.J. Costa, T.L. Parker, M. Levy, M. Schreder,
N. Meuleman, L. Frenzel, M. Mohty, S. Choquet, G. Schiller, R.L. Comenzo,
M. Engelhardt, T. Illmer, P. Vlummens, C. Doyen, T. Facon, L. Karlin, A. Perrot,
K. Podar, M.G. Kauffman, S. Shacham, L. Li, S. Tang, C. Picklesimer,
J.-R. Saint‑Martin, M. Crochiere, H. Chang, S. Parekh, Y. Landesman,
J. Shah, P.G. Richardson, and S. Jagannath

A BS T R AC T
BACKGROUND

Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1
(XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins,
inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a
potential novel treatment for myeloma that is refractory to current therapeutic options.
METHODS

We administered oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly to
patients with myeloma who had previous exposure to bortezomib, carfilzomib, lena
lidomide, pomalidomide, daratumumab, and an alkylating agent and had disease
refractory to at least one proteasome inhibitor, one immunomodulatory agent, and
daratumumab (triple-class refractory). The primary end point was overall response,
defined as a partial response or better, with response assessed by an independent
review committee. Clinical benefit, defined as a minimal response or better, was a
secondary end point.

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Address reprint requests to
Dr. Jagannath at the Tisch Cancer Institute, Icahn School of Medicine at Mount
Sinai, 1470 Madison Ave., 3rd Fl., New
York, NY 10029, or at s undar.jagannath@
mountsinai.org.
Drs. Richardson and Jagannath contributed equally to this article.
N Engl J Med 2019;381:727-38.
DOI: 10.1056/NEJMoa1903455
Copyright © 2019 Massachusetts Medical Society.

RESULTS

A total of 122 patients in the United States and Europe were included in the modified
intention-to-treat population (primary analysis), and 123 were included in the safety
population. The median age was 65 years, and the median number of previous regi
mens was 7; a total of 53% of the patients had high-risk cytogenetic abnormalities. A
partial response or better was observed in 26% of patients (95% confidence interval,
19 to 35), including two stringent complete responses; 39% of patients had a minimal
response or better. The median duration of response was 4.4 months, median progres
sion-free survival was 3.7 months, and median overall survival was 8.6 months. Fa
tigue, nausea, and decreased appetite were common and were typically grade 1 or 2
(grade 3 events were noted in up to 25% of patients, and no grade 4 events were re
ported). Thrombocytopenia occurred in 73% of the patients (grade 3 in 25% and grade
4 in 33%). Thrombocytopenia led to bleeding events of grade 3 or higher in 6 patients.
CONCLUSIONS

Selinexor–dexamethasone resulted in objective treatment responses in patients with
myeloma refractory to currently available therapies. (Funded by Karyopharm Thera
peutics; STORM ClinicalTrials.gov number, NCT02336815.)
n engl j med 381;8
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espite the availability of proteasome inhibitors, immunomodulatory
agents, and monoclonal antibodies for
multiple myeloma, most patients will have a
relapse and refractory disease will develop. An
increasing number of patients have triple-class
refractory myeloma, defined as disease refrac
tory to proteasome inhibitors, immunomodula
tory agents, and monoclonal antibodies, with
most patients being treated with all five agents
currently in use (carfilzomib, bortezomib, lena
lidomide, pomalidomide, and daratumumab; i.e.,
penta-exposed). Overall survival in patients with
myeloma refractory to these classes is short;
patients with daratumumab-refractory myelo
ma have a median overall survival of 1.7 to 3.0
months.1-4 Currently, these patients have no
treatment options with proven clinical benefit.4,5
Exportin 1 (XPO1) — the sole known nuclear
exporter of tumor suppressor proteins, the gluco
corticoid receptor, and oncoprotein messenger
RNAs (mRNAs) — is overexpressed in myeloma
and correlates with increased bone disease and
shorter survival.6-11 Selinexor, which was recently
approved by the Food and Drug Administration,
is a potent, oral, selective inhibitor of nuclear
export that binds to Cys528 in the cargo-binding
pocket of XPO1,12-14 forcing the nuclear localiza
tion and functional activation of tumor-suppres
sor proteins, trapping IκBα in the nucleus to
suppress nuclear factor κB activity, and prevent
ing oncoprotein mRNA translation.9,10,15 Selective
induction of apoptosis in malignant hemato
logic and solid tumor cells is a result.9 Preclini
cal studies have shown that selinexor with or
without dexamethasone induces apoptosis in a
number of myeloma cell lines and has antitumor
activity in animal models.3,8,9,16,17
Administration of selinexor (80 mg) with
dexamethasone (20 mg) according to two dosing
schedules had been evaluated among patients
with myeloma refractory to either four or five
drugs in Part 1 of the phase 2 STORM (Selinex
or Treatment of Refractory Myeloma) study.18 In
that heterogeneous population, 21% of patients
had a partial response or better. On the basis of
those findings, the activity of selinexor at a dose
of 80 mg twice weekly was examined in a more
uniform population in the pivotal STORM Part 2
study.
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Me thods
Trial Design and Oversight

The STORM study was a phase 2b, multicenter,
open-label study involving patients enrolled
from May 2015 through March 2018 at 60 sites
in the United States and Europe. The institu
tional review board or independent ethics com
mittee at each study center approved the proto
col (available with the full text of this article at
NEJM.org), and the study was performed in ac
cordance with the International Conference on
Harmonisation Good Clinical Practice guidelines
and the principles of the Declaration of Helsinki.
The study was designed by the sponsor (Karyo
pharm Therapeutics). Disease response was ad
judicated by an independent review committee
of four physicians. The sponsor collected the
data and analyzed them in conjunction with the
authors. A professional medical writer, funded
by the sponsor, wrote the first draft of the
manuscript under close direction of the authors.
The authors reviewed and revised the manu
script, had access to all data, and vouch for the
completeness and accuracy of the data and for
the adherence of the study to the protocol.
Patients

Eligible patients had measurable myeloma accord
ing to International Myeloma Working Group
(IMWG) criteria19,20 (see the Supplementary Ap
pendix, available at NEJM.org); had previously
received treatment with bortezomib, carfilzomib,
lenalidomide, pomalidomide, daratumumab, glu
cocorticoids, and an alkylating agent; and had
disease refractory to at least one immunomodu
latory drug, one proteasome inhibitor, daratumu
mab, glucocorticoids, and their most recent
regimen. Refractory disease was defined as
progression during treatment or within 60 days
after completion of therapy, or less than 25%
response to therapy.19,20 An Eastern Cooperative
Oncology Group performance-status score of
0 to 2 (scores range from 0 to 5, with higher
scores reflecting greater disability) and adequate
hepatic function, renal function, and hemato
poietic function were required. Systemic lightchain amyloidosis, active central nervous system
involvement, peripheral neuropathy of grade 3
or higher, or painful neuropathy of grade 2 or
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higher were exclusion criteria. A full list of inclu
sion and exclusion criteria is provided in Table S1
in the Supplementary Appendix. Written informed
consent was obtained from all patients before
enrollment.

and 12-lead electrocardiography. Adverse events
were graded according to the National Cancer
Institute Common Terminology Criteria for Ad
verse Events, version 4.03.23
Pharmacodynamics and Response Predictor

Treatment

Oral selinexor (80 mg) in combination with
dexamethasone (20 mg) was administered on
days 1 and 3, weekly, in 4-week cycles until dis
ease progression, death, or discontinuation. A
dose-modification protocol was used for the
management of adverse events (Tables S2 and S3
in the Supplementary Appendix). All patients
were required to receive 8 mg of ondansetron (or
equivalent) before the first dose of study drug
and two or three times daily as needed. Other
antiemetics (olanzapine and neurokinin-1 recep
tor antagonists) were permitted for patients with
unacceptable side effects to ondansetron (or its
equivalent) or with persistent nausea. Supportive
measures were provided at the discretion of the
investigator and may have included intravenous
fluids, hematopoietic growth factors, transfu
sions, appetite stimulants (olanzapine and meges
trol acetate), or a combination of these.
End Points and Assessments

The primary end point was overall response,
defined as a confirmed partial response (≥50%
reduction in the serum level of myeloma protein)
or better, with response adjudicated by the inde
pendent review committee.21 Secondary end points
included response duration; clinical benefit, de
fined as a confirmed minimal response (≥25 to
<50% reduction in the serum level of myeloma
protein) or better; progression-free survival; and
overall survival. (Definitions of end points are
provided in the Supplementary Appendix.) Diseasespecific assessments were conducted at baseline,
day 1 of each treatment cycle, and at the time of
disease progression or suspected response. Highrisk cytogenetic abnormalities included del(17p),
t(4;14), t(14;16), and gain(1q) chromosomal abnor
malities on fluorescence in situ hybridization.22
Quality of life was assessed with the Functional
Assessment of Cancer Therapy–Multiple Myeloma
questionnaire (see the protocol). Safety and sideeffect profile were assessed through history tak
ing, physical examination, laboratory assessments,

n engl j med 381;8

Methods regarding measurement of XPO1 mRNA
induction and immunohistochemical analysis of
glucocorticoid receptor induction are included in
the Supplementary Appendix. A predictive bio
marker of response to selinexor was sought in
patients with myeloma with the use of the VIPER
(Virtual Inference of Protein-activity by Enriched
Regulon analysis) algorithm, which can trans
form gene-expression profiles from tumor sam
ples into accurate predictions of protein activ
ity for approximately 6000 regulatory proteins
(DarwinHealth) (see the Supplementary Appen
dix).24 RNA levels in CD138+ cells that were
isolated from the pretreatment bone marrow
aspirate of patients enrolled in the STORM Part 2
study were used for this analysis.
Statistical Analysis

The sample size was based on assumptions for
penta-exposed, triple-class refractory myeloma
with a minimal threshold of 10% of patients
with a partial response or better.19 For the pri
mary efficacy analysis, a sample of 122 patients
allowed for a one-sided test at an alpha level of
0.025 to detect a minimum of 20% of patients
with a partial response or better against a value
of 10% under the null hypothesis with 90%
power. The modified intention-to-treat popula
tion was used for the primary efficacy analysis;
this population comprised all enrolled patients
who met all eligibility criteria or received a
waiver to enroll from the sponsor (12 patients;
waivers were granted only in situations in which
patient safety was not compromised and the
scientific integrity of the study was not affected)
and who received at least one dose of selinexor
plus dexamethasone. The safety population in
cluded all patients who received at least one dose
of study drug. The primary analysis used a twosided, exact 95% confidence interval, calculated
for the percentage of patients with a partial
response or better in the modified intention-totreat population, with statistical significance
declared if the lower boundary of this interval
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was more than 10%. Summary statistics were
computed and displayed for each of the defined
analysis populations and according to each as
sessment time point. Summary statistics for con
tinuous variables minimally included number,
mean, standard deviation, minimum, median,
and maximum. For categorical variables, frequen
cies and percentages are presented. For time-toevent variables, the Kaplan–Meier method was
used for descriptive summaries.

R e sult s

m e dic i n e

Treatment Duration and Doses

Of the 123 patients enrolled, 118 (96%) discon
tinued treatment, with disease progression and
adverse events the most common reasons (Table
S1 in the Supplementary Appendix). At the last
date of follow-up (August 17, 2018), 5 patients
(4%) continued to receive treatment; 34 (28%)
had discontinued treatment and remained in
follow-up for long-term survival. The median
duration of treatment with selinexor plus dexa
methasone was 9.0 weeks (range, 1 to 60).
Efficacy

Patients

A total of 123 patients were enrolled, all of
whom were included in the safety population
(Fig. S1 in the Supplementary Appendix). One
patient did not meet full eligibility criteria (no
previous carfilzomib); therefore, 122 patients
were included in the modified intention-to-treat
population. The median age was 65.2 years, and
the median duration of myeloma was 6.6 years;
53% of the patients had high-risk cytogenetic
abnormalities (Table 1, and Table S4 in the
Supplementary Appendix). All patients had pro
gressive myeloma at the time of enrollment, and
the disease was typically rapidly progressive: 107
patients (88%) with available data on myeloma
protein levels at both screening and the first day
of therapy (median, 12 days) had a median in
crease in disease burden of 22%. Creatinine
clearance was less than 60 ml per minute in 39
patients (32%) and less than 40 ml per minute
in 14 patients (11%). The median number of
previous therapies was 7 (range, 3 to 18); 86
patients (70%) had previously received daratumu
mab in combination with other agents, 102 (84%)
had previously undergone stem-cell transplanta
tion, and 2 (2%) had previously received chime
ric antigen receptor T-cell (CAR-T) therapy. In the
modified intention-to-treat population, all pa
tients had penta-exposed myeloma that was re
fractory to at least one proteasome inhibitor, one
immunomodulatory drug, and daratumumab, as
required by the protocol. A total of 83 patients
(68%) were documented to have penta-refractory
myeloma. It is notable that 96% of the patients
had myeloma that was refractory to the most
potent agent of each class: carfilzomib, pomalid
omide, and daratumumab (Table 1).
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A partial response or better was observed in 26%
of patients (95% confidence interval [CI], 19 to 35),
including 2 stringent complete responses (in 2%
of the patients), 6 very good partial responses (in
5%), and 24 partial responses (in 20%) (Table 2);
because the lower boundary of the confidence
interval was more than 10%, the trial met its
primary end point. Both patients with relapse
after CAR-T therapy had a partial response.
Minimal response according to IMWG criteria
was observed in 16 patients (13%), and 48 pa
tients (39%) had stable disease, whereas 26 (21%)
had progressive disease or disease that could not
be evaluated for response. The median time to a
partial response or better was 4.1 weeks (range,
1 to 14). A minimal response or better was
observed in 39% of patients (95% CI, 31 to 49).
Additional response analyses are shown in Ta
ble 2. The median duration of response was
4.4 months (95% CI, 3.7 to 10.8) (Fig. 1). The
median progression-free survival was 3.7 months
(95% CI, 3.0 to 5.3), and the median overall
survival was 8.6 months (95% CI, 6.2 to 11.3)
(Fig. 2A and 2B). In patients who had a partial
response or better or a minimal response or bet
ter, the median overall survival was 15.6 months
(Fig. 2C).
Safety Profile

The most common adverse events that emerged
during treatment were thrombocytopenia (in 73%
of the patients), fatigue (in 73%), nausea (in
72%), and anemia (in 67%) (Table 3). The most
common grade 3 or 4 adverse events were
thrombocytopenia (in 59% of the patients), ane
mia (in 44%), hyponatremia (in 22%), and neu
tropenia (in 21%). Thrombocytopenia occurred
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Table 1. Baseline Demographic and Clinical Characteristics in the Modified Intention-to-Treat Population.*
Value
(N = 122)

Characteristic
Age
Median (range) — yr

65.2 (40–86)

Distribution — no. (%)
18–50 yr

8 (7)

51–64 yr

52 (43)

65–75 yr

44 (36)

>75 yr

18 (15)

Male sex — no. (%)

71 (58)

ECOG performance-status score — no. (%)†
0

36 (30)

1

71 (58)

2

11 (9)

Missing data

4 (3)

Chromosomal abnormality — no. (%)
High risk overall‡

65 (53)

del(17p)/p53

32 (26)

t(4;14)

17 (14)

t(14;16)

5 (4)

gain(1q)

40 (33)

Median time since initial diagnosis (range) — yr

6.6 (1.1–23.4)

Median no. of previous treatment regimens (range)

7 (3–18)

Previous therapies to which the disease was refractory — no. (%)§
≥1 Immunomodulatory drug, ≥1 proteasome inhibitor, and daratumumab

122 (100)

Carfilzomib, pomalidomide, and daratumumab

117 (96)

Carfilzomib, lenalidomide, pomalidomide, and daratumumab

101 (83)

Bortezomib, carfilzomib, pomalidomide, and daratumumab

94 (77)

Bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab¶

83 (68)

*	A total of 123 patients were enrolled; 1 patient did not meet eligibility criteria, so 122 patients were included in the
modified intention-to-treat population. Percentages may not total 100 because of rounding.
†	Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores reflecting greater disability.
‡	This category includes any of del(17p)/p53, t(14;16), t(4;14), or 1q21 (1q gain >2).
§	The disease was defined as refractory to an antimyeloma therapy if the best response to the therapy was stable disease
or worse or if the patient had progression or a relapse either during treatment or within 60 days after discontinuing the
therapy.
¶	Myeloma that was refractory to these five agents was considered to be penta-refractory.

more frequently in patients who had thrombocy
topenia at baseline than in those who did not
(Fig. S2 in the Supplementary Appendix), and six
patients with thrombocytopenia of grade 3 or
higher had a concurrent bleeding event of grade 3
or higher. Most nonhematologic adverse events

n engl j med 381;8

were limited in severity to grades 1 or 2, with
only 10% of patients having grade 3 nausea and
3% having grade 3 vomiting.
In all, 18% of the patients discontinued study
treatment because of an adverse event considered
by the investigator to be related to selinexor or
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Table 2. Overall Response and Clinical Benefit.*
Patients
Included
in Analysis

Variable

Patients with
Partial Response
or Better

number
Total

Patients with
Minimal Response
or Better

number (percent)

122

32 (26)

48 (39)

83

21 (25)

31 (37)

Previous therapies to which the disease was refractory
Bortezomib, carfilzomib, lenalidomide, pomalidomide,
and daratumumab
Carfilzomib, lenalidomide, pomalidomide, and daratumumab

101

26 (26)

37 (37)

Bortezomib, carfilzomib, pomalidomide, and daratumumab

94

25 (27)

36 (38)

117

31 (26)

45 (38)

20

7 (35)

10 (50)

II

78

21 (27)

32 (41)

III

23

4 (17)

6 (26)

35

15 (43)

19 (54)

Carfilzomib, pomalidomide, and daratumumab
R-ISS disease stage
I

Measurable free light chains
Yes
No
High-risk cytogenetic abnormality†

87

17 (20)

29 (33)

65

12 (18)

24 (37)

*	Overall response was defined as a partial response (≥50% reduction in the serum level of myeloma protein) or better,
and clinical benefit was defined as a minimal response (≥25% to <50% reduction in the serum level of myeloma protein)
or better. Among the 122 patients, the best response to therapy was a stringent complete response in 2 (2%), a very
good partial response in 6 (5%), a partial response in 24 (20%), a minimal response in 16 (13%), stable disease in 48
(39%), and progressive disease or disease that could not be evaluated for response in 32 (26%). R-ISS denotes Revised
International Staging System.
†	This category included any of del(17p)/p53, t(14;16), t(4;14), or 1q21 (1q gain >2).

dexamethasone, although such determinations
for a new agent are imprecise (Table S5 in the
Supplementary Appendix). Adverse events lead
ing to dose modification or interruption oc
curred in 80% of the patients, with the majority
of events occurring in the first two cycles. The
most common adverse events leading to dose
reduction or interruption were thrombocytope
nia (in 43% of the patients), fatigue (in 16%),
and neutropenia (in 11%). Supportive care — in
cluding granulocyte colony-stimulating factors,
thrombopoietin-receptor agonists, appropriate
fluid and caloric intake, appetite stimulants,
psychostimulants, and additional antinausea
agents — usually reduced the intensity or dura
tion of adverse events. Side effects were revers
ible without evidence of toxic effects in major
organs (treatment-related cardiac, pulmonary,
hepatic, or renal dysfunction of grade 3 or
higher) or cumulative toxic effects, with irreversible
acute kidney injury reported in one patient (1%).
732

n engl j med 381;8

Serious adverse events occurred in 63% of the
patients, with pneumonia (in 11%) and sepsis
(in 9%) being the most common (Table S6 in the
Supplementary Appendix). A total of 28 patients
died during the study — 16 from disease pro
gression and 12 from an adverse event. In the 12
patients with these adverse events, 2 events were
assessed by the investigator as being related to
treatment (pneumonia with concurrent disease
progression [in 1 patient] and sepsis [in 1]).
Biomarkers of Selinexor Response in Multiple
Myeloma

The binding of selinexor to XPO1 leads to rapid
inactivation of nuclear export, XPO1 protein deg
radation, and induction of XPO1 mRNA tran
scription (without new protein production).9 XPO1
mRNA induction is one pharmacodynamic mark
er in selinexor-treated patients, as observed from
blood samples obtained before and after selinexor
administration, as well as enhanced glucocorti
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No response yet

Minimal response

Partial response

Very good partial
response

Stringent complete
response
*

Patients with Partial Response or Better
(N=32)

*

*
*
*

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

Treatment Duration (mo)

Figure 1. Duration of Response to Treatment.
An asterisk indicates that the patient was still receiving treatment at the date of data cutoff.

coid receptor nuclear localization (Fig. S5 in the
Supplementary Appendix).25,26 A model based on
a linear discriminant analysis classifier that was
trained on 35 pretreatment patient samples, includ
ing 16 obtained from patients who had a response
and 19 from patients who did not have a re
sponse, identified four master regulators: IRF3,
ARL2BP, ZBTB17, and ATRX (Fig. S7 in the Sup
plementary Appendix). The four-protein classifier
had a high predictive performance according to
leave-one-out cross-validation (area under the
receiver-operating-characteristic curve [AUC], 0.862;
95% CI, 0.741 to 0.982). The four-protein classifier
was then validated in an independent, blinded
analysis of 12 samples obtained from patients
with myeloma who were enrolled in Parts 1 and 2
of the STORM study (AUC, 0.770; 95% CI, 0.456
to 1.000). Specifically, four of five patients who
had a response and six of seven who did not have
a response to selinexor were correctly identified
by the marker, yielding a prediction accuracy of
83% (95% CI, 55 to 95). Training the classifier
with the use of differential gene-expression data
alone produced no effective classification.
n engl j med 381;8

Discussion
In this trial, 26% of the patients with pentaexposed, triple-class refractory myeloma who
received oral selinexor, a first-in-class XPO1
inhibitor, with dexamethasone twice weekly had
a partial response or better. Two patients had
stringent complete responses, and 6 had very
good partial responses. Although all patients
entered the study with progressive disease, 26
(21%) had persistent disease progression or their
disease could not be evaluated for response.
Among the patients who had a response, efficacy
was consistent across subgroups, including pa
tients with high-risk cytogenetic abnormalities
(53% of the patients).
The results of this study are notable for sev
eral reasons. The trial was permissive, allowing
patients with reduced renal function, thrombo
cytopenia, and neutropenia to enroll. These pa
tients were heavily pretreated, with a median of
7 previous therapeutic regimens, including a me
dian of 10 unique antimyeloma agents. Patients
had rapidly progressing myeloma, with a 22%
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9

10

11

12

13

14

15

16

17

10
13
10
2

8
10
6
1

8
10
4
0

6
6
3

4
4
3

3
3
1

2
2
1

1
1
0

Months
No. at Risk
PR or better
MR or better
Best response, SD
Best response, PD or NE
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32
48
48
26

32
48
45
17

31
46
42
11

29
42
33
9

27
40
30
8

24
36
24
8

22
33
19
7

19
27
15
6
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Table 3. Adverse Events That Emerged during Treatment.*
Event

Grade 1

Grade 2

Grade 3

Grade 4

Total
(N = 123)

number (percent)
≥1 Adverse event

123 (100)

Hematologic adverse events
Thrombocytopenia

12 (10)

6 (5)

31 (25)

41 (33)

90 (73)

Anemia

7 (6)

22 (18)

53 (43)

1 (1)

83 (67)

Neutropenia

7 (6)

16 (13)

22 (18)

4 (3)

49 (40)

Leukopenia

8 (7)

16 (13)

17 (14)

0

41 (33)

Lymphopenia

2 (2)

4 (3)

10 (8)

4 (3)

20 (16)

Fatigue

16 (13)

43 (35)

31 (25)

0

90 (73)

Nausea

34 (28)

42 (34)

12 (10)

0

88 (72)

Decreased appetite

22 (18)

41 (33)

6 (5)

0

69 (56)

Decreased weight

34 (28)

27 (22)

1 (1)

0

62 (50)

Diarrhea

32 (26)

15 (12)

9 (7)

0

56 (46)

Vomiting

22 (18)

21 (17)

4 (3)

0

47 (38)

Hyponatremia

18 (15)

0

26 (21)

1 (1)

45 (37)

3 (2)

23 (19)

2 (2)

0

28 (23)

16 (13)

9 (7)

2 (2)

0

27 (22)

Dyspnea

11 (9)

11 (9)

5 (4)

0

27 (22)

Cough

14 (11)

7 (6)

0

0

21 (17)

Hypokalemia

10 (8)

3 (2)

8 (7)

0

21 (17)

Insomnia

13 (11)

6 (5)

2 (2)

0

21 (17)

Nonhematologic adverse events

Upper respiratory tract infection
Constipation

Mental status changes

7 (6)

7 (6)

7 (6)

0

21 (17)

0

8 (7)

10 (8)

1 (1)

21 (17)†

Dizziness

14 (11)

5 (4)

0

0

19 (15)

Pyrexia

11 (9)

8 (7)

0

0

19 (15)

Epistaxis

11 (9)

3 (2)

1 (1)

0

15 (12)

Pneumonia

Fall

9 (7)

4 (3)

2 (2)

0

15 (12)

Hyperglycemia

2 (2)

3 (2)

8 (7)

0

13 (11)

Peripheral edema

8 (7)

3 (2)

2 (2)

0

13 (11)

Blurred vision

8 (7)

3 (2)

2 (2)

0

13 (11)

*	Shown are events that occurred in at least 10% of the patients. Adverse events were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.23
†	The total includes two events of grade 5.

Figure 2 (facing page). Kaplan–Meier Analysis of Progression-free Survival, Overall Survival, and Overall Survival According to Response.
CI denotes confidence interval, MR minimal response, NE not able to be evaluated, PD progressive disease, PR partial response, and SD
stable disease. Tick marks indicate censored data.
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increase in disease burden in the 12 days from
screening to initial therapy. These characteris
tics are consistent with the growing population
of patients who have exhausted available thera
pies but still desire to continue therapy.
Given the rapid progression of penta-exposed,
triple-class refractory myeloma, the window of
opportunity to prevent further illness and death
is small. Therefore, the regimen that was used
in the STORM study began with a high dose of
selinexor to achieve rapid disease control. Because
most patients involved in the study were older
and frail, with limited end-organ reserve and at
increased risk for adverse events, dose modifica
tions were anticipated and were specified along
with supportive care in the protocol. The adverse
events that were observed in the study were a func
tion of dose, schedule, and baseline clinical char
acteristics (e.g., cytopenias). Thrombocytopenia,
which is due in part to inhibition by selinexor of
thrombopoietin signaling in early megakaryo
poiesis, was reversible and was managed with
dose interruptions and thrombopoietin-receptor
agonists.27 Although this study establishes the
activity of selinexor with dexamethasone, com
bination regimens are typically used in patients
with myeloma. Preclinical studies of selinexor
show enhancement of IκB, which supports its
synergy in combination with proteasome inhibi
tors, additivity with immunomodulatory drugs,
and sensitization of myeloma cells to anti-CD38
monoclonal antibodies.28-30
In conclusion, the results of the STORM Part 2
study showed that oral selinexor with low-dose
dexamethasone induced responses in 26% of pa
tients with refractory myeloma. The most com
mon toxic effects of grade 3 or higher included
thrombocytopenia without bleeding, anemia, neu
tropenia without fever, and hyponatremia.
A data sharing statement provided by the authors is available
with the full text of this article at NEJM.org.
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